With the emergence of new medications with weight loss and cardiovascular benefits as well as biosimiliar insulins, clinicians need easier point-of-care access to evidence-based tools to support more personalized management and improve patient health outcomes.
E2P’s EMR-integrated Prediabetes and Type 2 Diabetes tool for TELUS PS Suite, OSCAR Pro, and Accuro QHR supports primary care by giving them easier access to the information they need at the point of care.
Purpose of the Tool
- Support the early identification of patients at risk
- Monitor and assess glycemic targets
- Provide patient education and coaching resources
Tool Features
Prevention and management: Identifying and flagging pre-diabetic patients while monitoring patient response to treatment for type 2 diabetes through pharmacological therapies.
Screening and assessment: Assists in screening for risk factors, diagnoses, and complications for prediabetes and diabetes using standardized testing.
Support for patients: Enables identification of self-management therapies and streamlined navigation of available services and supports, tailored to individual patient needs.
Interested in implementing E2P’s Prediabetes and Type 2 Diabetes tool in your practice?
Already using another E2P tool?
Implementation and Change Management Support
Change Management Specialists
eHealth Centre of Excellence’s Change Management Specialists are available, free of charge, to enable the smooth adoption and effective utilization of the E2P Prediabetes and Type 2 Diabetes tool.
- Tailored coaching and support for primary care clinicians, allied health professionals and all clinic staff
- Facilitated installation, set-up and tool training
- Review of existing workflows to maximize
efficiencies
Academic Detailing Service
The Centre for Effective Practice provides, free of charge, 1-on-1 discussions with a trained clinical pharmacist to support clinician educational needs and build capacity and confidence to deliver best patient care, including:
- Transitioning patients on brand-name insulin glargine, aspart, or lispro, to a biosimilar brand insulin
- Considering factors beyond A1C lowering, when selecting non-insulin pharmacotherapy
Development Process
Tools and supports for prediabetes and type 2 diabetes were co-developed with primary and acute care clinicians, persons with lived experiences, experts and key system stakeholders.
Topic Expert Group
A warm thank you to the Topic Expert Group who supported the development of these E2P tools and supports:
- Risa Bordman MD CCFP(PC) FCFP
- Vicki Lee, MPH
- Sarah McTavish, MSc
- Geetha Mukerji, MD MSc FRCPC
- Nicole J. Ranger MD, CCFP
- Marlene Rathbone, Lived Experience Advisor
- Kevin Samson, MD, BASc
- Tharsan Sivakumar, MD, MPH, FRCPC
- Denis Tsang, MSc, RD, CDE, CHE
- Tom Weisz, B.A., DCh, IIWCC, Lived Experience Advisor
- Valerie Winberg MN, NP-PHC